ExRNA in Biofluids as Biomarkers for Brain Tumors
- First Online:
- Cite this article as:
- Rennert, R.C., Hochberg, F.H. & Carter, B.S. Cell Mol Neurobiol (2016) 36: 353. doi:10.1007/s10571-015-0284-5
- 587 Downloads
Patients with high-grade gliomas and glioblastomas (GBMs) have poor survival despite optimal surgical and drug therapy. Minimally invasive diagnostic biomarkers would enable early diagnosis and tumor-specific treatments for ‘personalized targeted’ therapy, and would create the basis for response tracking in patients with GBM. Extracellular vesicles (EVs) isolated from cerebrospinal fluid and blood contain glioma-specific molecules, including tumor-derived EV RNAs that are detectable in small copy numbers in these biofluids. EV RNA mutations or expression changes are also detectable, the analysis of which gives rise to ‘liquid biopsy’ tumor profiling.